<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604276</url>
  </required_header>
  <id_info>
    <org_study_id>1100316-599</org_study_id>
    <nct_id>NCT03604276</nct_id>
  </id_info>
  <brief_title>Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage</brief_title>
  <acronym>HASH4-CSF</acronym>
  <official_title>Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage (HASH4-CSF) - An Observational Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maine Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relationship between the Neuroinflammatory
      response and headache pain after subarachnoid hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent headache is a significant medical issue that affects 20% of patients who survive
      an aneurysmal subarachnoid hemorrhage (SAH). This headache may last years, severely affecting
      quality of life. Laboratory evidence suggests that the persistent headache may be a result of
      a maladaptive neuroinflammatory response to the hemorrhage injury that is more vigorous than
      necessary. The goal of this study is to measure key immunomodulators in the blood and the
      cerebrospinal fluid of these patients in order to determine the magnitude and dynamics of
      their neuroinflammatory response. In addition, the investigators will collect and analyze
      observational data about the success of medications to treat headache, with a specific focus
      on the anti-inflammatory agent dexamethasone, in managing acute headache pain and preventing
      the development of persistent headaches in patients after SAH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of the neuroinflammatory response in the CSF and blood of patients with non-traumatic SAH.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of correlation between the neuroinflammatory response and severity/presence of headache pain.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of correlation between the neuroinflammatory response and development of chronic headache.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the neuroinflammatory response in the CSF and blood in patients treated with dexamethasone versus other analgesics post SAH.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of dexamethasone versus other analgesics in their ability to improve measures of quality of life.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Headache</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients are patients with a non-traumatic subarachnoid hemorrhage who are treated
        with an external ventricular drain for symptomatic hydrocephalus.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-traumatic subarachnoid hemorrhage

          -  Age &gt; 18 years

          -  Treated with external ventricular drainage

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Age &lt; 18 years

          -  Traumatic SAH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth K Glisic, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maine Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Eldridge, BSN, RN</last_name>
    <phone>207-662-3231</phone>
    <email>eldria@mmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Lord, BSN, RN-BC</last_name>
    <phone>207-662-5206</phone>
    <email>lordc@mmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Eldridge, BSN, RN</last_name>
      <phone>207-662-3231</phone>
      <email>eldria@mmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maine Medical Center</investigator_affiliation>
    <investigator_full_name>Elizabeth Glisic</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Subarachnoid hemorrhage</keyword>
  <keyword>Neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

